PIK3CA and breast carcinoma: Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)‐positive, human epidermal growth factor receptor (HER) 2‐negative advanced breast cancer.